ArticleApplied microbiology and biotechnology2015
Bacillus subtilis as heterologous host for the secretory production of the non-ribosomal cyclodepsipeptide enniatin.
Article in Applied microbiology and biotechnology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 71 citations in OpenAlex.
- DevelopingFrontiers in microbiology · 2026Article
- Highly efficient genome editing inSynthetic and systems biotechnology · 2025Article
- Engineering bacterial cell morphology for the design of robust cell factories.Biochemistry and biophysics reports · 2025Review
- A new paradigm for the regulation of A40926B0 biosynthesis.Synthetic and systems biotechnology · 2025Article
- Response surface methodology to optimize theJournal of food science and technology · 2025Article
- Recent advances on cyclodepsipeptides: biologically active compounds for drug research.Frontiers in microbiology · 2023Review
- An efficient CRISPR/Cas9-based genome editing system for alkaliphilic Bacillus sp. N16-5 and application in engineering xylose utilization for D-lactic acid production.Microbial biotechnology · 2022Article
- A host-vector toolbox for improved secretory protein overproduction in Bacillus subtilis.Applied microbiology and biotechnology · 2022Article
- Efficient Large-Scale and Scarless Genome Engineering Enables the Construction and Screening ofInternational journal of molecular sciences · 2022Article
- Microbial production of small peptide: pathway engineering and synthetic biology.Microbial biotechnology · 2021Review
- Current State and Future Directions of Genetics and Genomics of Endophytic Fungi for Bioprospecting Efforts.Frontiers in bioengineering and biotechnology · 2021Review
- Design and Construction of Portable CRISPR-Cpf1-Mediated Genome Editing inFrontiers in bioengineering and biotechnology · 2020Article
- Advances in targeting and heterologous expression of genes involved in the synthesis of fungal secondary metabolites.RSC advances · 2019Review
- Genetic platforms for heterologous expression of microbial natural products.Natural product reports · 2019Review
- Recent advances in CRISPR/Cas9 mediated genome editing in Bacillus subtilis.World journal of microbiology & biotechnology · 2018Review
- CopySwitch-Frontiers in bioengineering and biotechnology · 2018Article
- Article
- Engineered polyketides: Synergy between protein and host level engineering.Synthetic and systems biotechnology · 2017Review
- A Highly Efficient CRISPR-Cas9-Mediated Large Genomic Deletion inFrontiers in microbiology · 2017Article
- Simple and rapid direct cloning and heterologous expression of natural product biosynthetic gene cluster in Bacillus subtilis via Red/ET recombineering.Scientific reports · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The heterologous expression of genes or gene clusters in microbial hosts, followed by metabolic engineering of biosynthetic pathways, is key to access industrially and pharmaceutically relevant compounds in an economically affordable and sustainable manner. Therefore, platforms need to be developed, which provide tools for the controlled synthesis of bioactive compounds. The Gram-positive bacterium Bacillus subtilis is a promising candidate for such applications, as it is generally regarded as a safe production host, its physiology is well investigated and a variety of tools is available for its genetic manipulation. Furthermore, this industrially relevant bacterium provides a high secretory potential not only for enzymes but also for primary and secondary metabolites. In this study, we present the first heterologous expression of an eukaryotic non-ribosomal peptide synthetase gene (esyn) coding for the biosynthesis of the small molecule enniatin in B. subtilis. Enniatin is a pharmaceutically used cyclodepsipeptide for treatment of topical bacterial and fungal infections. We generated various enniatin-producing B. subtilis strains, allowing for either single chromosomal or plasmid-based multi-copy expression of the esyn cluster under the control of an acetoin-inducible promoter system. Optimization of cultivation conditions, combined with modifications of the genetic background and multi-copy plasmid-based esyn expression, resulted in a secretory production of enniatin B. This work presents B. subtilis as a suitable host for the expression of heterologous eukaryotic non-ribosomal peptide synthetases (NRPS) clusters.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.